Americas

This fact sheet describes Chemistry, Manufacturing, and Controls (CMC) work at PATH. It covers what CMC is and why it's important, where we work, our capabilities, and how interested parties can reach out to us for collaboration opportunities.

This year’s annual report features our annual financial overview, a list of PATH’s funders and supporters, and our accomplishments in 2021.

The Novartis Foundation launched an online artificial intelligence (AI) in health maturity assessment tool to help decision-makers identify where to best invest resources to enable successful deployment of impactful AI solutions in health. The tool was initially rolled out to six countries in 2021 and 2022: Argentina, Brazil, Chile, Philippines, Uruguay, and Vietnam; using a collaborative process that engaged key stakeholder groups, including representatives from the ministry of health, international nongovernmental organizations, civil society, private sector, and health organizations.This white paper shares an overview of the experience these countries had in conducting the self assessment. It also articulates the themes that emerged across countries and the various recommendations made to further explore AI in health to help address the challenges health systems face.

Medical oxygen proved to be a lifesaving drug during the COVID-19 pandemic in the absence of a proven therapeutic solution for patients suffering from the infection. In May 2021, India's health infrastructure was overwhelmed by the caseload, with a lack of oxygen, manpower, drugs, and hospital beds. The most difficult challenge for the country was providing an adequate volume of medical oxygen for the most severely ill patients who were unable to breathe on their own.PATH, with its extensive experience in respiratory care management, responded quickly and played a critical role in strengthening the oxygen ecosystem at this critical juncture. It provided technical assistance in the installation and procurement of PSA oxygen generation plants and oxygen concentrators, as well as improved their readiness.Furthermore, in order to build capacity for long-term sustainability, PATH developed, translated, and disseminated high-quality, reliable, and ready-reference knowledge products, such as the Guidebook on Medical Oxygen Management, Oxygen Posters, Standard Operating Procedures, Checklists, Case Studies, and Success Stories on various aspects of the oxygen ecosystem.

This document, current as of May 25, 2022, provides data and information from PATH's modeling focused on the global supply and demand of autodisable (AD) syringes, which are used for COVID-19 and routine immunizations in more than 100 countries. The current forecast indicates that, despite an estimated gap of 360 million AD syringes in Q 1 2022, production capacity is adequate to meet syringe demand in Q2 2022 through Q3 2023, due to the significant capacity expansions undertaken by manufacturers and slower COVID-19 vaccination uptake than targeted timelines in many countries. The AD syringe gap analysis combines maximum syringe supply capacity collected from manufacturers in Q2 2022 with estimated syringe demand from all countries known to use AD syringes globally, including demand for both COVID- 19 and non-COVID-19 immunizations. Three potential scenarios for AD syringe demand are forecasted to reflect the uncertainty in future demand; the forecast indicates adequate supply in all three scenarios.

Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included a feasibility and acceptability study with national stakeholders and healthcare providers in Ghana, Kenya, Malawi, Peru, Senegal, and Sri Lanka to assess their preferences for different hypothetical rotavirus vaccine options. These briefs provide an overview of the results in each of the study countries.

Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included: targeted analyses on the ideal age group for iNGRVs and potential future combination vaccine options, impact and cost effectiveness analyses, a feasibility and acceptability study with national stakeholders and healthcare providers in six countries, and a demand forecast. This brief provides a comprehensive summary of the results.

Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included an impact and cost-effectiveness analysis examining multiple rotavirus vaccine options and strategies. This fact sheet provides an overview of the results.